Calcium carbonate ( DrugBank: Calcium, Calcium carbonate, Carbonate )

---

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
19	ライソゾーム病	1
46	悪性関節リウマチ	1
53	シェーグレン症候群	1
75	クッシング病	1
96	クローン病	1
235	副甲状腺機能低下症	4
299	嚢胞性線維症	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00785473 (ClinicalTrials.gov)	January 2008	4/11/2008	Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis	Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study	Multiple Sclerosis, Osteoporosis	Dietary Supplement: cholecalciferol;Dietary Supplement: calcium carbonate	University Hospital of North Norway	NULL	Completed	18 Years	50 Years	Both	80	Phase 4	Norway

19. ライソゾーム病

---

臨床試験数 : 899 /  薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004488 (ClinicalTrials.gov)	October 1998	18/10/1999	Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease		Gaucher's Disease;Osteopenia	Drug: alendronate sodium;Drug: calcium carbonate;Drug: cholecalciferol	Children's Hospital Medical Center, Cincinnati	NULL	Completed	18 Years	50 Years	Both	82	Phase 2	United States;Israel

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00000429 (ClinicalTrials.gov)	June 1996	18/1/2000	Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis	Calcium Supplementation for Bone Mineralization in Juvenile Rheumatoid Arthritis (JRA)	Juvenile Rheumatoid Arthritis	Drug: Calcium carbonate	Children's Hospital Medical Center, Cincinnati	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	6 Years	18 Years	Both	192	Phase 2	United States

53. シェーグレン症候群

---

臨床試験数 : 305 /  薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02370550 (ClinicalTrials.gov)	March 2015	18/2/2015	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Sjogren's Syndrome	Drug: Cyclosporin A;Drug: Prednisone;Drug: Placebo;Drug: Calcium carbonate D	Peking University People's Hospital	NULL	Recruiting	18 Years	75 Years	All	240	Phase 4	China

75. クッシング病

---

臨床試験数 : 205 /  薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-002280-14-FR (EUCTR)	18/07/2008	06/06/2008	Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial	Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial	The Active substance of Osteopor is Ossein Hydroxyapatite.Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis. MedDRA version: 9.1;Level: LLT;Classification code 10006956;Term: Calcium deficiency	Trade Name: OSTEOPOR Product Name: OSTEOPOR Product Code: L0006CP03A INN or Proposed INN: ossein hydroxyapatite Trade Name: OROCAL Product Name: OROCAL INN or Proposed INN: calcium carbonate	Pierre Fabre Médicament	NULL	Not Recruiting			Female: yes Male: no	60	Phase 3	France

96. クローン病

---

臨床試験数 : 2,442 /  薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01735461 (ClinicalTrials.gov)	December 2012	22/11/2012	Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients	Oral Calcium Supplementation, a Strategy to Reduce Kidney Stones in Crohn's Patients Living With a Small Bowel Resection	Kidney Calculi;Crohn's Disease	Dietary Supplement: Calcium Carbonate	University of British Columbia	University of Texas Southwestern Medical Center	Recruiting	19 Years	N/A	All	40	N/A	Canada

235. 副甲状腺機能低下症

---

臨床試験数 : 88 /  薬物数 : 107 - (DrugBank : 24) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03425747 (ClinicalTrials.gov)	October 15, 2019	27/1/2018	Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism	CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM	Chronic Hypoparathyroidism	Drug: Calcium Carbonate;Drug: Calcium Citrate	Campus Bio-Medico University	NULL	Completed	18 Years	75 Years	All	26	Phase 4	Italy
2	NCT04146259 (ClinicalTrials.gov)	January 1, 2017	29/10/2019	Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism	Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism	Hypoparathyroidism Postprocedural	Drug: calcium carbonate and alphacalcidol	University of Athens	NULL	Completed	19 Years	N/A	Female	109		Greece
3	NCT01815021 (ClinicalTrials.gov)	April 2013	7/3/2013	A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients	A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.	Hypoparathyroidism	Dietary Supplement: amorphous calcium carbonate;Dietary Supplement: crystalline calcium supplements	Amorphical Ltd.	NULL	Completed	18 Years	80 Years	Both	10	Phase 1/Phase 2	Israel
4	JPRN-UMIN000000475	2006/07/01	01/09/2006	Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration	Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration - The effect of sevelamer hydrochloride on relative hypoparathyroidism in hemodialysis patients	Relative hypoparathyoidism in maintenance hemodialysis patients	Replacement of calcium carbonate with sevelamer hydrochloride as phosphate binder	Hokusetsu ROD Study Group	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	40	Not applicable	Japan

299. 嚢胞性線維症

---

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004489 (ClinicalTrials.gov)	October 1998	18/10/1999	Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis		Osteoporosis;Cystic Fibrosis	Drug: alendronate sodium;Drug: calcium carbonate;Drug: cholecalciferol	University of North Carolina	NULL	Completed	18 Years	45 Years	Both	60	N/A	United States

先頭へ